Clinical trials: Depressed Mood
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Depression, Depressive Symptoms
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Conditions
- Depression, Depressive Symptoms, Mood
- Trial name
- VITAL-DEP (NCT01696435)
- Testing
- vitamin D3, omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 18,353 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Depression
Treatments for Improving Mood in Depressed Teens-3
Phase 3 is a randomized clinical trial of yoga vs group Cognitive Behavioral Therapy (CBT) for adolescents with depression.
- Trial name
- TeenThrive (NCT03831360)
- Testing
- Yoga, Group CBT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Depressive Disorder, Pregnancy
EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy
The purpose of this study is to assess the effectiveness of the EnBrace HR prenatal supplement in preventing depression in women with a history of depression who have decided to stop taking antidepressants during their pregnancy…
- Trial name
- NCT02676882
- Testing
- EnBrace HR
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
- Trial name
- NCT00596622
- Testing
- Lithium
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Major Depressive Disorder
Mini Theta Burst TMS in MDD Patients
This is not a treatment study. In this study, the researchers are primarily interested in examining whether functional MRI (fMRI)-guided transcranial magnetic stimulation (TMS) may be more effective than traditional TMS methods…
- Trial name
- NARSAD (NCT04014959)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Clinical Study of Generic and Brand Bupropion in Depression
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
- Trial name
- BALANCE (NCT02209597)
- Testing
- Bupropion XL 300
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD).
- Trial name
- Geodon (NCT00555997)
- Testing
- Ziprasidone
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depression, Bipolar
Olanzapine Treatment of Patients With Bipolar I Disorder
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
- Trial name
- NCT00510146
- Testing
- Olanzapine
- Where
- 16 sites in China, Japan and 1 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp